To understand whether NF-κB and IKK are involved in AREG-induced cancer cell migration, we treated osteosarcoma cells with a NF-κB inhibitor(PDTC) and an IKK inhibitor (TPCK). Here, NFKB1 is linked to osteosarcoma.